Page 3 - பல்கலைக்கழகம் புற்றுநோய் ஆராய்ச்சி நிறுவனம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Sarah Silbiger via Getty Images A group of advisers to the Food and Drug Administration this week recommended the agency maintain four of six recent cancer immunotherapy approvals despite a lack of evidence the medicines help patients live longer.  The positive votes, which took place over an unusual three-day meeting, could push the FDA to keep drugs from Roche, Bristol Myers Squibb and Merck & Co. on the market while the companies complete additional studies to confirm their benefit. The FDA typically, though not always, follows the advice of its advisory committees. If the FDA does adhere to the panel votes, regulators could fuel further criticism that the agency isn t holding drugmakers to the terms of the accelerated approval pathway it s used to make new cancer drugs available quickly. 

United statesRichard pazdurAndrew hertlerRoche tecentriqDaina grayboschBishal gyawaliPhilip hoffmanIan waxmanJulia beaverBristol myersOncology centerQueen university cancer research institute in ontarioDrug administrationMerck coUniversity of coloradoCentury health